← back to search

Tommaso Tonetti

University of Perugia · IT
Area of research
Pulmonary and Respiratory Medicine · Infectious Diseases
Research interest
Research interests include Respiratory Support and Mechanisms, COVID-19 Clinical Research Studies, Cardiac Arrest and Resuscitation, and Antibiotics Pharmacokinetics and Efficacy.
h-index
38
citations
7,862
works
130
NIH funding
primary concept
Medicine
email

Recent publications

Contemporary local anaesthetic-associated adverse events and mortality: searching for the root causes of the pharmacovigilance signal. Br J Anaesth 2026;136:411–13
British Journal of Anaesthesia 2026cited by 0position: contributordoi
Personalizing beta-lactams therapy in critical patients undergoing RRT: moving a further step forward?
2026cited by 0position: contributordoi
Acute Respiratory Distress Syndrome and Fluid Management: Finding the Perfect Balance.
2025cited by 3position: contributordoi
TDM-Based Approach for Properly Managing Intravenous Isavuconazole Treatment in a Complex Case Mix of Critically Ill Patients.
2025cited by 1position: contributordoi
Mechanical power and VILI: modeling limits and unknowns.
2025cited by 0position: contributordoi
Reply to Yang and to Xie and Wang.
2025cited by 0position: contributordoi
Lung-Protective Mechanical Ventilation in Patients with Severe Acute Brain Injury: A Multicenter Randomized Clinical Trial (PROLABI)
American Journal of Respiratory and Critical Care Medicine 2024cited by 34position: lastdoi
Lung-Protective Mechanical Ventilation in Patients with Severe Acute Brain Injury: A Multicenter Randomized Clinical Trial (PROLABI).
2024cited by 27position: contributordoi
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study.
2024cited by 10position: contributordoi
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
2024cited by 1position: contributordoi
Association between respiratory distress time and invasive mechanical ventilation in COVID-19 patients: A multicentre regional cohort study.
2024cited by 0position: contributordoi
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?
2023cited by 11position: contributordoi
Current knowledge gaps in extracorporeal respiratory support.
2023cited by 9position: contributordoi
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia.
2023cited by 9position: contributordoi
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF).
2023cited by 8position: contributordoi
Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial
Journal of Intensive Care 2023cited by 6position: middledoi
Increased duration and similar outcomes of V-V ECLS in patients with COVID-19 ARDS compared to non-COVID ARDS: Single center experience.
2023cited by 4position: contributordoi
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
2023cited by 2position: contributordoi
High-Flow Nasal Oxygen for Severe Hypoxemia: Oxygenation Response and Outcome in Patients with COVID-19.
2022cited by 47position: contributordoi
Individualized positive end-expiratory pressure guided by end-expiratory lung volume in early acute respiratory distress syndrome: study protocol for the multicenter, randomized IPERPEEP trial
Trials 2022cited by 15position: middledoi
Clinical implications of microvascular CT scan signs in COVID-19 patients requiring invasive mechanical ventilation
La radiologia medica 2022cited by 12position: middledoi
Reply to Barahona-Correa <i>et al</i>.: High-Flow Oxygen Therapy for Severe Hypoxemia: Moving toward a More Inclusive Definition of Acute Respiratory Distress Syndrome.
2022cited by 0position: contributordoi
Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure
JAMA 2021cited by 497position: middledoi
Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study.
2021cited by 87position: contributordoi
Sustained oxygenation improvement after first prone positioning is associated with liberation from mechanical ventilation and mortality in critically ill COVID-19 patients: a cohort study
Annals of Intensive Care 2021cited by 82position: middledoi
Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up study
Respiratory Medicine 2021cited by 80position: middledoi
Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up study.
2021cited by 66position: contributordoi
Quality of life of COVID-19 critically ill survivors after ICU discharge: 90 days follow-up
Quality of Life Research 2021cited by 63position: middledoi
Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections.
2021cited by 58position: contributordoi
The lower respiratory tract microbiome of critically ill patients with COVID-19.
2021cited by 53position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 30 papers (2019–2026)Milo Gatti · Alma Mater Studiorum Universita' di Bologna7 papers (2021–2025)Massimo Antonelli · University of Nevada, Las Vegas6 papers (2020–2024)Federico Pea · Azienda USL di Bologna6 papers (2021–2025)Michele Bartoletti · Azienda USL di Bologna5 papers (2020–2021)Matteo Rinaldi · University of Bologna5 papers (2021–2023)Massimo Girardis · University of Modena and Reggio Emilia4 papers (2020–2024)Paolo Navalesi · University of Padua4 papers (2020–2022)V. Marco Ranieri · Azienda USL di Bologna3 papers (2020–2023)Domenico Luca Grieco · Unity Health Toronto3 papers (2021–2022)Maddalena Giannella · Azienda USL di Bologna3 papers (2020–2021)Giacomo Grasselli · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico3 papers (2021–2023)Paolo Gaibani · University of Verona3 papers (2021–2023)Alessandro De Cassai · University of Padua3 papers (2018–2019)Arthur S. Slutsky · Toronto Rehabilitation Institute2 papers (2021–2022)Thomas Länger · Medical College of Wisconsin2 papers (2020–2021)Vanni Agnoletti · University College London2 papers (2020–2021)Savino Spadaro · Heinrich Heine University Düsseldorf2 papers (2020–2021)Cristiana Laici · Azienda USL di Bologna2 papers (2021–2021) · 2 papers (2021–2022)